{"schema_version":"secwatch.filing_event.v1","accession":"0001217234-22-000185","form_type":"8-K","ticker":"CDNA","cik":"0001217234","company_name":"CareDx, Inc.","filed_at":"2022-11-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:49.868478+00:00","generated_at":"2026-06-22T08:09:06.351487+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"CareDx Q3: Revenue $79.4M (+5%), net loss widens to $16.9M; adj EBITDA loss $2.5M","bullets":["Revenue $79.4M (+5% YoY); testing services $64.8M, product $7.2M, patient/digital $7.4M.","Net loss $16.9M ($0.32 per share) vs $11.9M loss ($0.23) in Q3 2021.","Non-GAAP net loss $3.4M vs non-GAAP income $4.0M; non-GAAP EPS -$0.06 vs +$0.07.","Adjusted EBITDA loss $2.5M vs gain $4.7M; company targets positive adjusted EBITDA by H1 2023.","Delivered 46,500 patient test results (+15% YoY); cash $291.3M, no debt."],"urls":{"canonical":"https://secwatch.observer/filing/0001217234-22-000185","json":"https://secwatch.observer/filing/0001217234-22-000185.json","markdown":"https://secwatch.observer/filing/0001217234-22-000185.md","text":"https://secwatch.observer/filing/0001217234-22-000185.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1217234/000121723422000185/0001217234-22-000185-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1217234/000121723422000185/cdna-20221103.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T08:09:06.351487+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"428ca69a67d92f495820cebbc642a5c414dfe213","claim":"CareDx, Inc. reported the third quarter ended September 30, 2022 results: revenue $79.4 million, net income net loss was $16.9 million, EPS $0.32.","evidence_excerpt":"with positive adjusted EBITDA by first half of 2023 • Delivered 46,500 patient test results, representing growth of 15% compared to third quarter of 2021 • Achieved revenue of $79.4 million, increasing 5% year-over-year • Sustained strong testing services GAAP gross margin of 73% and non-GAAP gross margin of 74% • Strong balance sheet with $291 million cash, cash","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1217234/000121723422000185/0001217234-22-000185-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the third quarter ended September 30, 2022"},{"label":"Revenue","value":"$79.4 million"},{"label":"Net income","value":"net loss was $16.9 million"},{"label":"EPS","value":"$0.32"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}